Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease

Inc., a clinical-stage biotechnology company developing novel small molecule therapies to modulate critical RNA targets, ...
PMLive

Skyhawk Therapeutics’ SKY-0515 shows positive results in Huntington’s disease

Skyhawk Therapeutics has announced positive interim results from its phase 1 trial of SKY-0515, an investigational treatment ...
HDBuzz

Phase 1 results announced for Skyhawk’s drug SKY-0515

Skyhawk Therapeutics shared results for SKY-0515, a drug designed to lower huntingtin. The drug appeared generally safe, with 60% reduction of huntingtin in blood at the highest dose tested. This data ...